Australia, Nov. 18 -- Azurity Pharmaceuticals Inc., owns the trademark (2548063) for 'FIRVANQ' till April 9, 2035.
Status: protected:
Registered/protected
Class: 5 [Antibiotics; pharmaceutical preparations, namely, vancomycin for the treatment of colitis and gastrointestinal disorders in oral solution form, powder form and diluent form; pharmaceutical preparations, namely, vancomycin for the treatment of clostridium difficile and staphylococcus aureus colitis in oral solution form, powder form and diluent form.]
Type of Mark: Word
Date of Acceptance: June 9
Registration Advertised: Nov. 17
For further details contact Greenfield & Sacks P.C. Douglas R. Wolf Wolf.
The original document can be viewed at: https://search.ipaustralia.gov.a...